TW
ABBV icon

TrinityPoint Wealth’s AbbVie ABBV Stock Holding History

TrinityPoint Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$10.3M Buy
58,169
+318
+0.5% +$58.5K 1.45% 9
2024
Q3 		$11.4M Buy
57,851
+31
+0.1% +$5.79K 1.64% 9
2024
Q2 		$9.92M Sell
57,820
-863
-1% -$143K 1.55% 10
2024
Q1 		$10.7M Buy
58,683
+653
+1% +$113K 1.77% 9
2023
Q4 		$8.99M Sell
58,030
-4,151
-7% -$605K 1.63% 9
2023
Q3 		$9.27M Buy
62,181
+666
+1% +$97.8K 1.85% 7
2023
Q2 		$8.29M Buy
61,515
+1,273
+2% +$187K 1.62% 8
2023
Q1 		$9.6M Buy
60,242
+1,314
+2% +$201K 2.06% 7
2022
Q4 		$9.52M Buy
58,928
+367
+0.6% +$56.3K 2.17% 6
2022
Q3 		$7.86M Buy
58,561
+161
+0.3% +$23.1K 1.8% 9
2022
Q2 		$8.95M Buy
58,400
+4,416
+8% +$675K 1.98% 8
2022
Q1 		$8.75M Buy
53,984
+3,640
+7% +$529K 1.58% 10
2021
Q4 		$6.82M Buy
50,344
+144
+0.3% +$17K 1.21% 14
2021
Q3 		$5.42M Buy
50,200
+795
+2% +$90.8K 1.04% 19
2021
Q2 		$5.57M Buy
49,405
+423
+0.9% +$47.6K 1.14% 16
2021
Q1 		$5.3M Buy
48,982
+436
+0.9% +$46.6K 1.23% 16
2020
Q4 		$5.28M Buy
48,546
+16,065
+49% +$1.54M 1.27% 14
2020
Q3 		$2.85M Buy
32,481
+19,784
+156% +$1.86M 0.79% 31
2020
Q2 		$1.25M Buy
12,697
+185
+1% +$16.3K 0.39% 71
2020
Q1 		$953K Buy
12,512
+1,582
+14% +$135K 0.38% 72
2019
Q4 		$968K Sell
10,930
-6,109
-36% -$507K 0.33% 74
2019
Q3 		$1.41M Buy
17,039
+9,704
+132% +$665K 0.49% 53
2019
Q2 		$495K Sell
7,335
-165
-2% -$13K 0.24% 100
2019
Q1 		$604K Buy
7,500
+4,479
+148% +$366K 0.3% 89
2018
Q4 		$278K Buy
+3,021
New +$266K 0.17% 127

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

TrinityPoint Wealth's ABBV Position: Q4 2024 in Review

TrinityPoint Wealth increased its AbbVie (ABBV) stake by 0.55% in Q4 2024, buying an estimated $58.5K and bringing the position to 58,169 shares worth $10.3M. The position accounts for 1.45% of the portfolio, ranked #9.

TrinityPoint Wealth first reported a position in ABBV in Q4 2018 and has held it in 25 quarters since. The position peaked at $11.4M in Q3 2024. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • TrinityPoint Wealth held 58,169 shares of AbbVie worth $10.3M as of Q4 2024.
  • TrinityPoint Wealth bought 318 AbbVie shares in Q4 2024, an estimated $58.5K.
  • AbbVie made up 1.45% of TrinityPoint Wealth's portfolio in Q4 2024, its #9 holding.
  • TrinityPoint Wealth first reported a position in AbbVie in Q4 2018 and has held it in 25 quarters since.
  • TrinityPoint Wealth's AbbVie position peaked at $11.4M in Q3 2024.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on TrinityPoint Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.